Article Type
Editorial
Published
This editorial examines lipocrinology, the study of the interrelationship between lipid metabolism and endocrine function in health and disease
Drugs in Context Endocrinology welcomes a broad range of article types including original research, study protocols and review articles.
In line with the principle of providing context for healthcare professionals (HCPs) to properly inform and improve disease management in real world medicine, we especially encourage the submission of articles that provide context for trials of drug interventions in order to motivate improvements in disease management by HCPs practising medicine in the front line.
Editorial
This editorial examines lipocrinology, the study of the interrelationship between lipid metabolism and endocrine function in health and disease
Review
Examines combining a dihydropyridine calcium channel blocker with a renin-angiotensin-aldosterone system inhibitor for the treatment of diabetes
Original Research
This article reports on the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.
Review
This paper summarizes the results from the ground-breaking EMPA-REG OUTCOME study and discusses their significance and clinical implications.
Case Report
Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of antidiabetes agents with an insulin-independent mechanism of action, making them suitable for use in combination with any other class of antidiabetes agents, including insulin. In this review the evaluates a 78-week, randomized, double-blind, placebo controlled trial investigating the impact of empagliflozin, an SGLT2 inhibitor, as add-on to basal insulin in patients with inadequate glycemic control on basal insulin, with or without metformin and/or a sulfonylurea.